Stockscreener 앱 받기
54.22
1.88%
-1.04
시간 외 거래:
54.35
0.13
+0.24%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb (BMY) Upgraded to Buy by UBS, Noting a Skewed Risk/Reward Ratio for the Stock - Yahoo Finance UK
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - TradingView — Track All Markets
Bristol Myers, Microsoft Aim To Catch Lung Cancer Early With New AI Tool - Benzinga
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035 - Yahoo Finance
Microsoft (MSFT) and Bristol Myers Squibb (BMY) Partner to Enhan - GuruFocus
Bristol Myers partners with Microsoft for AI-driven lung cancer detection - Reuters
Guggenheim Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $62 - 富途资讯
Bristol Myers partners with Microsoft for AI-driven lung cancer detection By Reuters - Investing.com
Bristol Myers (BMY) Teams Up with Microsoft for Lung Cancer Dete - GuruFocus
Bristol Myers Squibb Partners With Microsoft On AI Lung Cancer Detection - Nasdaq
Bristol Myers Squibb and Microsoft partner to detect lung cancer earlier - Investing.com
Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026 - Finviz
2 Dividend Stocks to Buy and Hold For 10 Years - Finviz
Syngene expands research collaboration with Bristol Myers Squibb - The Economic Times
Immunai and Bristol Myers Squibb sign AI partnership - jpost.com
Syngene extends Bristol Myers Squibb research partnership till 2035 - scanx.trade
Syngene International Extends Research Partnership With Bristol Myers Squibb Through 2035 - scanx.trade
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock With a Path to Growth - Chartmill
2 Top Blue-Chip Stocks to Buy and Hold in 2026 - morningstar.com
How Is The Market Feeling About Bristol-Myers Squibb Co? - Benzinga
Novo Nordisk, BioMarin make AI moves; Bristol Myers welcomes neurology exec from Eisai - Endpoints News
Another ADC foray for Bristol Myers Squibb - The Pharma Letter
Campbell & CO Investment Adviser LLC Has $5.81 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
The Bull Case For Bristol-Myers Squibb (BMY) Could Change Following Camzyos’ Phase 3 Adolescent oHCM Win - simplywall.st
Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY) - The Globe and Mail
Immunai and Bristol Myers Squibb turn to AI to decode immune responses in clinical trials - CTech
Stephens Inc. AR Raises Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Trading 1.9% Higher After Analyst Upgrade - MarketBeat
Rep. Gilbert Ray Cisneros, Jr. Buys Bristol Myers Squibb Company (NYSE:BMY) Shares - MarketBeat
Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients - Finviz
Bristol Says New Version of Opdivo on Track to Meet Target - Bloomberg.com
Leerink Partners Remains a Buy on Bristol-Myers Squibb (BMY) - The Globe and Mail
Manning & Napier Advisors LLC Lowers Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Pharmaceutical research and development pipeline - Bristol Myers Squibb
Leerink Partners Raises Price Target for Bristol-Myers Squibb (BMY) to $60 | BMY Stock News - GuruFocus
Leerink Partners Issues Positive Forecast for Bristol Myers Squibb (NYSE:BMY) Stock Price - MarketBeat
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Bristol Myers Squibb Company $BMY Position Raised by Sumitomo Mitsui Trust Group Inc. - MarketBeat
JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff - Pharmaceutical Technology
Bristol-Myers Squibb stock price target raised to $60 from $54 at Leerink - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by GRIMES & Co WEALTH MANAGEMENT LLC - MarketBeat
Worldwide locations - Bristol Myers Squibb
JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year - BioPharma Dive
AbbVie Becomes Latest To License PD-1xVEGF Bispecific In Growing Field - Citeline News & Insights
JPM26: Bristol Myers CEO to 'cast a broad net' as business development remains a top priority - Fierce Pharma
Scotiabank Raises Bristol-Myers (BMY) PT to $60 Citing Catalyst-Rich 2026 Growth - Finviz
Bristol Myers Squibb CEO Outlines 2030 Growth Strategy Focused on Oncology, Immunology, and Cardiovascular Expansion at JP Morgan Healthcare Conference - geneonline.com
Bristol-Myers Squibb Stock Under Pressure: Is This Deep-Value Pharma Name Finally Near a Turning Poi - AD HOC NEWS
Bristol-Myers Squibb Company (BMY) Releases New Investor Presentation - GuruFocus
Bristol-Myers Squibb Advances Liver Cancer Combo as Key Trial Reaches Completion - TipRanks
What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release - Barchart.com
Bristol Myers Squibb’s Camzyos shows positive results in adolescent oHCM trial - Investing.com
BMY Reports Positive Results from Phase 3 SCOUT-HCM Trial - GuruFocus
First Horizon Corp Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: A Pivotal Year Ahead as Sentiment Shifts - AD HOC NEWS
Nepsis Inc. Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Lecap Asset Management Ltd. Sells 19,756 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
How Recent Developments Are Shaping The Bristol Myers Squibb (BMY) Investment Story - Yahoo Finance
Did UBS’s Pipeline-Driven Upgrade Just Shift Bristol-Myers Squibb’s (BMY) Investment Narrative? - Yahoo Finance
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - TradingView — Track All Markets
Scotiabank raises Bristol-Myers Squibb stock price target to $60 on growth - Investing.com
Next Level Private LLC Has $2.54 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Scotiabank Adjusts Price Target on Bristol-Myers Squibb to $60 From $53, Maintains Sector Perform Rating - marketscreener.com
What RSI levels show for Bristol Myers Squibb Company (BRM) stockStock Surge & AI Enhanced Execution Alerts - ulpravda.ru
Is Bristol Myers Squibb Company Celegne Contingent stock attractive post correctionMarket Performance Report & Consistent Growth Equity Picks - ulpravda.ru
1.82%
0.18%
자본화:
|
볼륨(24시간):